Amgen and AstraZeneca report Phase 3 CROSSING trial results for TEZSPIRE in eosinophilic esophagitis
The Phase 3 CROSSING trial showed TEZSPIRE achieved histologic remission in 64.8% (210 mg) and 68.9% (420 mg) of patients at week 24 versus 3.5% on placebo (p<0.001). The Dysphagia Symptom Questionnaire score decreased by 18.8 points (210 mg) and 22.0 points (420 mg) versus 14.7 points on placebo, with reductions sustained through week 52.
Primary source
Company press release (PR Newswire), October 20, 2026
TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS
Read the source: TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS prnewswire.com
Machine-summarized from the source above; not independently reported. How we use automation